African-Americans equally likely to benefit from erlotinib and other targeted lung cancer therapy

African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

Read the whole article on Physorg

More from Physorg